Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

January 24, 2017
Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In an announcement on Jan. 3, the Shanghai-based immunotherapy and stem cell therapy company said it was expanding cell production in China to enable production of personalized CAR-T treatments in China for 10,000 patients annually. The company is focusing on becoming a leader in the area in China, but is manufacturing therapies according to both Chinese and US standards, Liu said in an interview at Biotech Showcase.
Previous Video
Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery
Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound ...

Next Video
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the t...